Abstract 608P
Background
Mucosal melanoma (MM) is a rare and aggressive subtype of melanoma arising from mucosal surfaces. While MMs are distinct from cutaneous melanomas (CMs) in pathogenesis, etiology and prognosis, management of both subtypes has remained largely similar, as the rarity of the disease poses a challenge to developing evidence-based clinical guidelines for MM. We performed a meta-analysis on the use of immune checkpoint inhibitors (ICIs) and targeted therapy for MM.
Methods
We searched five databases (PubMed, Cochrane, Embase, Web of Science and Google Scholar) for studies evaluating the efficacy of ICIs and targeted therapy in the treatment of locally advanced or metastatic MMs. After including only cohort and observational studies with available overall survival (OS) and progression free survival (PFS) data, the eligible studies comprised patients treated with anti-PD1, anti-CTLA4, VEGFR inhibitors or tyrosine kinase inhibitors (TKIs). For single-arm and double-arm studies that reported Kaplan-Meier curves, we digitally reconstructed individual patient data using Guyot's algorithm and calculated the OS, PFS and hazard ratios, along with the 95% confidence intervals.
Results
We included 26 studies with a total of 1911 participants. Our results show that combined anti-PD1 and anti-CTLA4 therapy had the highest 12-month OS and 12-month PFS at 0.677 (0.608,0.754) and 0.388 (0.316,0.475) respectively. This was followed by anti-PD1 therapy alone (OS: 0.602 (0.569,0.638); PFS: 0.282 (0.251,0.317)), anti-PD1 and VEGFR inhibitor combination therapy (OS: 0.506 (0.437,0.585)), TKI therapy (OS: 0.482 (0.376,0.618); PFS: 0.083 (0.037,0.187)) and anti-CTLA4 therapy alone (OS: 0.333 (0.284,0.391); PFS: 0.098 (0.059,0.165)). In the double-arm studies, anti-PD1 and anti-CTLA4 combination therapy had similar OS and PFS with anti-PD1 treatment alone (OS: HR 0.866 (0.616,1.22); PFS: HR 0.848 (0.666,1.08)), however, anti-PD1 therapy alone had significantly better PFS than anti-CTLA4 alone (HR 0.548 (0.376,0.799)).
Conclusions
Collectively, these results demonstrate that anti-PD1 and anti-CTLA4 combination therapy has the most favorable outcome in the treatment of MM, while anti-PD1 therapy is the single best agent.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
441P - The prophylactic efficacy of telpegfilgrastim, a Y-shape branched pegylated G-CSF in patient with chemotherapy-induced neutropenia: A multicenter, randomized phase III study
Presenter: Xinshuai Wang
Session: Poster Display
Resources:
Abstract
442P - Negative impact on bone homeostasis in postmenopausal women with non-metastatic breast cancer during cytotoxic chemotherapy
Presenter: Yadav Nisha
Session: Poster Display
Resources:
Abstract
443P - Efficacy of vitamin D supplementation in overall survival of cancer patients: Systematic review and meta-analysis
Presenter: Visakha Irawan
Session: Poster Display
Resources:
Abstract
444P - Commencing a nurse led symptom and urgent review clinic (SURC) in a Victorian regional cancer centre
Presenter: Sue Bartlett
Session: Poster Display
Resources:
Abstract
445P - Self-reported symptom burden, quality of life and unmet need of symptom management in nasopharyngeal cancer survivors: A cross-sectional survey
Presenter: Jerry Ching
Session: Poster Display
Resources:
Abstract
446P - A single center experience of anamorelin in patients with non-small cell lung cancer
Presenter: Takanori Ito
Session: Poster Display
Resources:
Abstract
447P - Quality of life in patients with EGFR-mutated lung cancer receiving gefitinib vs gefitinib plus pemetrexed and carboplatin chemotherapy
Presenter: Nandini Menon
Session: Poster Display
Resources:
Abstract
448P - Association of clinicopathological characteristics and pro-inflammatory markers with reduced relative dose intensity in breast cancer chemotherapy
Presenter: Susanna Hutajulu
Session: Poster Display
Resources:
Abstract
449P - Psychometric validation of the MD Anderson symptom inventory head&neck module: Chinese version in nasopharyngeal cancer survivors
Presenter: Victor Tam
Session: Poster Display
Resources:
Abstract
450P - Retrospective study of anamorelin therapy for unresectable or recurrent pancreatic cancer with cancer cachexia
Presenter: Mao Okada
Session: Poster Display
Resources:
Abstract